Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6% – What’s Next?

Jyong Biotech Ltd. (NASDAQ:MENS) was down 9.6% on Tuesday . The company traded as low as $31.53 and last traded at $31.99. Approximately 96,739 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 289,113 shares. The stock had previously closed at $35.40.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Jyong Biotech Price Performance

The stock has a fifty day moving average price of $48.57.

Institutional Trading of Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets acquired a new position in Jyong Biotech Ltd. (NASDAQ:MENS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.